Comprehensive Clinical Guide: Endoscopic Hemostasis via Sclerotherapy (EVS)

1. Introduction and Overview

Endoscopic Variceal Sclerotherapy (EVS) remains a cornerstone intervention in the management of portal hypertension-related complications, specifically esophageal variceal hemorrhage. As a therapeutic endoscopic technique, EVS involves the direct injection of a sclerosant agent into or adjacent to esophageal varices. The primary clinical objective is to induce thrombosis, inflammation, and subsequent fibrosis of the vascular lumen, effectively obliterating the varix and preventing both active bleeding and future re-bleeding episodes.

While Endoscopic Variceal Ligation (EVL) has become the first-line treatment for many clinicians due to its favorable safety profile, EVS maintains a critical role in clinical practice, particularly when varices are too small for banding, when the patient’s anatomy precludes the use of a banding device, or as an adjunctive therapy in refractory cases. This guide serves as an authoritative clinical resource for gastroenterologists, hepatologists, and specialized nursing staff involved in the management of cirrhotic patients.

2. Technical Specifications and Mechanisms of Action

The efficacy of EVS relies on the chemical induction of vascular damage. The sclerosant agent creates an immediate inflammatory response followed by a proliferative phase that leads to tissue remodeling and luminal obliteration.

Mechanisms of Action

1. Endothelial Damage: The chemical agent directly injures the vascular endothelium, exposing the subendothelial collagen.
2. Thrombus Formation: Exposure of the basement membrane triggers the coagulation cascade, promoting the formation of a thrombus within the varix.
3. Inflammatory Response: A local inflammatory reaction occurs within the esophageal wall (esophagitis), which promotes cellular infiltration.
4. Fibrosis: Over 7–21 days, the thrombus is replaced by fibrous connective tissue, permanently obliterating the varix and reducing the risk of rupture.

Common Sclerosing Agents

3. Clinical Indications and Usage

EVS is indicated for patients with documented portal hypertension secondary to cirrhosis or non-cirrhotic portal hypertension.

Primary Indications

• Active Variceal Hemorrhage: Used for emergency hemostasis when ligation is technically difficult.
• Secondary Prophylaxis: Prevention of re-bleeding in patients who have already experienced a variceal bleed.
• Refractory Varices: Cases where EVL has failed to eradicate varices or where residual varices persist after multiple ligation sessions.
• Small-Caliber Varices: Varices that cannot be captured effectively within the ligation device barrel.

Patient Pre-operative Preparation

1. Hemodynamic Stabilization: Prior to endoscopy, ensure the patient is resuscitated with fluids and, if necessary, blood products (target hemoglobin >7 g/dL).
2. Airway Protection: In cases of massive hematemesis, endotracheal intubation is mandatory to prevent aspiration.
3. Antibiotic Prophylaxis: Administration of intravenous ceftriaxone (or equivalent) is the standard of care to prevent spontaneous bacterial peritonitis (SBP).
4. Coagulation Correction: While often difficult in cirrhotic patients, correcting severe coagulopathy or thrombocytopenia is advisable, though not always mandatory for emergency procedures.
5. Sedation: Conscious sedation or general anesthesia (depending on patient stability) is required.

4. The Procedure: Step-by-Step Intervention

Step 1: Endoscopic Assessment

The endoscope is introduced, and the esophagus is cleared of blood/clots. Varices are assessed for "red signs" (cherry-red spots, hematocystic spots), which indicate a high risk of imminent rupture.

Step 2: Sclerosant Preparation

The sclerosant is loaded into a specialized sclerotherapy needle (typically 23-gauge). The needle is flushed with saline to ensure no air remains in the catheter.

Step 3: Injection Technique

• Intra-variceal: The needle is inserted directly into the varix. A small amount of blood is aspirated to confirm location. 1–3 mL of sclerosant is injected per site.
• Para-variceal: The needle is injected into the submucosal tissue adjacent to the varix to induce local edema, compressing the vessel from the outside.
• Sequence: Injections typically proceed from the gastroesophageal junction (GEJ) upward, moving in a spiral or circular pattern.

Step 4: Verification and Withdrawal

After injection, the needle is withdrawn, and the site is monitored for persistent bleeding. A "bleb" or blanching of the mucosa typically indicates successful placement.

5. Post-Operative Recovery and Protocol

• Monitoring: The patient must be monitored for 2–4 hours post-procedure for signs of immediate perforation or chest pain.
• Dietary Progression: Patients are typically kept NPO (nothing by mouth) for 6–12 hours, followed by a liquid diet for 24–48 hours to minimize mechanical trauma to the esophagus.
• PPI Therapy: High-dose Proton Pump Inhibitors (PPIs) are prescribed for 1–2 weeks to manage post-sclerotherapy esophagitis and ulceration.
• Follow-up: Repeat endoscopy is scheduled in 2–4 weeks to assess for residual varices and the need for further sessions.

6. Risks, Complications, and Contraindications

Potential Complications

1. Esophageal Ulceration: The most common side effect; occurs due to the necrotic nature of the sclerosant.
2. Esophageal Stricture: A long-term complication resulting from excessive scarring/fibrosis.
3. Perforation: A rare but life-threatening event requiring immediate surgical consultation.
4. Bacteremia: Risk of infection; reinforces the necessity for prophylactic antibiotics.
5. Pleural Effusion: Occurs secondary to mediastinal inflammation post-procedure.

Contraindications

• Absolute: Unstable cardiopulmonary status (until stabilized), uncorrected severe hypovolemic shock.
• Relative: Severe esophageal stricture, active esophagitis (non-variceal), or patient inability to tolerate general anesthesia if intubation is required.

7. Alternative Treatments

• Endoscopic Variceal Ligation (EVL): The gold standard for esophageal varices. Uses rubber bands to create a mechanical strangulation of the varix.
• Transjugular Intrahepatic Portosystemic Shunt (TIPS): A radiological procedure that creates a shunt between the portal vein and the hepatic vein to reduce portal pressure.
• Pharmacotherapy: Non-selective beta-blockers (e.g., propranolol) and vasoactive drugs (e.g., octreotide, terlipressin) used to reduce portal inflow.
• Balloon Tamponade: A temporary bridge therapy using a Sengstaken-Blakemore tube for uncontrollable, life-threatening hemorrhage.

8. Massive FAQ Section

Q1: Is EVS still relevant in the era of banding?

Yes. EVS is essential for small-caliber varices that are difficult to band and for gastric varices where banding is ineffective.

Q2: How many sessions are usually required?

Typically, 3–5 sessions are required at 2–4 week intervals to achieve complete variceal eradication.

Q3: What is the risk of esophageal perforation?

The risk is generally low (<1%), but it increases with the volume of sclerosant injected and the depth of the injection.

Q4: Why do we use antibiotics after EVS?

Patients with cirrhosis are immunocompromised. The procedure causes transient bacteremia, which can lead to SBP or infected ascites.

Q5: Can EVS cause chest pain?

Yes, retrosternal chest pain is a very common post-procedure symptom, usually managed with analgesics and PPIs.

Q6: What is the difference between intra-variceal and para-variceal injection?

Intra-variceal targets the vessel lumen directly; para-variceal induces perivascular fibrosis to compress the vessel.

Q7: When can a patient resume a normal diet?

Usually within 48–72 hours, provided there is no evidence of active bleeding or severe dysphagia.

Q8: What if the patient has a severe allergic reaction to the sclerosant?

The procedure must be aborted, and the patient treated with corticosteroids and antihistamines. Alternative sclerosants or ligation should be considered for future sessions.

Q9: Does EVS cure portal hypertension?

No. EVS treats the symptoms (varices) of portal hypertension but does not address the underlying liver disease or the portal pressure itself.

Q10: What are the signs of esophageal ulceration?

Patients may experience odynophagia (painful swallowing), persistent chest pain, or low-grade fever in the days following the procedure.

9. Conclusion

Endoscopic Variceal Sclerotherapy remains a vital, life-saving technique in the modern gastroenterologist’s armamentarium. By providing a chemically induced method of vessel obliteration, EVS bridges the gap where mechanical ligation falls short. Rigorous adherence to pre-operative stabilization, precise injection techniques, and comprehensive post-operative care is essential to minimizing complications and improving patient outcomes in the management of portal hypertension. As clinical practice evolves, the integration of EVS with pharmacological management and, where appropriate, TIPS, ensures a multifaceted approach to the high-mortality condition of variceal hemorrhage.